Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14) - Peters, Solange; Felip, Enriqueta; Dafni, Urania; Tufman, Amanda; Guckenberger, Matthias; Álvarez, Ruth; Nadal, Ernest; Becker, Annemarie; Vees, Hansjörg; Pless, Miklos; Martinez-Marti, Alex; Lambrecht, Maarten; et al. (Journal of thoracic oncology, 2021)
Keywords: Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Chemoradiotherapy; Disease-Free Survival; Humans; Immune checkpoint inhibition; Lung Neoplasms - pathology; Neoplasm Staging; Nivolumab; Nivolumab - therapeutic use; NSCLC; Reference Standards; Immune checkpoint inhibition; NSCLC; Chemoradiotherapy; Nivolumab